John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

EditorialPublication Exclusive

New data on late treatment effects should change physician–patient discussions

HemOnc Today, March 10, 2016
John Sweetenham, MD
Just over a year ago, my editorial for HemOnc Today focused on times when strongly held opinions can get in the way of an objective assessment of…
EditorialPublication Exclusive

Preparing for the journey to the moon

HemOnc Today, February 25, 2016
John Sweetenham, MD
The cancer challenge has received considerable and welcome attention in the media in recent months. Following word of increased funding for the NCI…
EditorialPublication Exclusive

Precision cancer care: The knowledge (and reality) gap

HemOnc Today, January 10, 2016
John Sweetenham, MD
Almost every day my email and regular mail have at least one article related to the growth of precision cancer care; the promise of genomics and…
EditorialPublication Exclusive

Given high stakes of cancer care, biosimilar debate requires an open mind

HemOnc Today, December 10, 2015
John Sweetenham, MD
In the last few months, I have followed the emerging debate about the use of biosimilars at a distance, but they have not impacted my clinical…
EditorialPublication Exclusive

Recent data on management of cancer in pregnant women may be cause for optimism

HemOnc Today, November 10, 2015
John Sweetenham, MD
I have had the privilege of taking care of many young adult patients with lymphomas. This group of patients poses unique challenges and rewards. Some…
EditorialPublication Exclusive

Cancer awareness months: Are we missing an opportunity or missing the point?

HemOnc Today, October 10, 2015
John Sweetenham, MD
I was recently reminded that October is Breast Cancer Awareness Month. Coincidentally, I had e-mails from two research charities with an interest in…
EditorialPublication Exclusive

The end(point) game in indolent lymphoma: After years-long search, data suggest genuine progress

HemOnc Today, September 10, 2015
John Sweetenham, MD
Evidence from several sources suggests that OS for patients with follicular lymphoma has improved in recent years. The reasons for this improvement…
EditorialPublication Exclusive

Research reveals fine line between ‘one more try’ and ‘a bridge too far’

HemOnc Today, August 25
John Sweetenham, MD
“I think we may be going a bridge too far.”  – Lt. Gen. Frederick Browning, prior to the First Allied Airborne Army’s…
EditorialPublication Exclusive

Drug cost debate must not detract from focus on value in cancer care

HemOnc Today, July 10, 2015
John Sweetenham, MD
We are all at various stages of readiness for the transition from volume-based to value-based care. The development of value-based care models is a…
EditorialPublication Exclusive

Liquid biopsies offer ‘transformative’ potential for detection of aggressive lymphomas

HemOnc Today, June 10, 2015
John Sweetenham, MD
This issue of HemOnc Today includes an article that describes a study from the NCI that investigated the use of circulating tumor DNA as a tumor…